Daniel C. Payne, Ph.D., MSPH
Senior Scientific Advisor for the Viral Gastroenteritis Branch at the US Centers for Disease Control and Prevention
He attended Emory University (BA), University of Alabama, Birmingham (MSPH) and Tulane University (Ph.D.) in New Orleans, Louisiana.
He is currently the Principal Investigator for the “New Vaccine Surveillance Network”, a multi-site network of large US medical institutions, and the primary US active surveillance network for acute gastroenteritis and acute respiratory illnesses in children. Published data from these surveillance studies provides new and clinically important information regarding the real-world effects of vaccines against childhood diseases and guides the development of new vaccines and improved vaccine strategies.
Dr. Payne is also the Principal Investigator for the PREVAIL Cohort (Pediatric Respiratory & Enteric Viral Acquisition and Immunogenesis Longitudinal Cohort), a prospective, longitudinal cohort of maternal-infant pairs. This cohort is designed to better understand the full range of maternal immunity imparted to infants and focuses on rotavirus, norovirus, RSV and influenza vaccine development and optimization.
In 2016 he became the Senior Technical Consultant for the Rotavirus Accelerated Vaccine Introduction Network (RAVIN), a grant funded by the Bill and Melinda Gates Foundation. Dr. Payne’s role as a CDC partner is to provide scientific support to ongoing country and partner efforts for rotavirus vaccine introduction in Asian and African Gavi-eligible countries.
Introduction of the presentation
Since 2006, the US Centers for Disease Control and Prevention has actively tracked rotavirus epidemiologic trends in US children and the impact and effectiveness of rotavirus vaccines.
Recently published material reflecting a variety of US rotavirus topics will be presented, including longitudinal observations of rotavirus vaccination in a NICU cohort, factors influencing rotavirus vaccine coverage in the US, and a follow-up study of household risks from rotavirus.
Furthermore, our new US rotavirus vaccine effectiveness results from the NVSN network will be presented, as well as early findings from our intensively followed PREVAIL cohort of US infants.